Hims & Hers Health (HIMS)
NYSE:HIMS
Top Page
Hims & Hers Health
(NYSE:HIMS)
Select Model
Select Model
Rating:58Neutral
Price Target:
$20.00
▲(2.93% Upside)
Action:ReiteratedDate:03/13/26
The score is primarily held back by higher financial risk from the sharp 2025 leverage increase and weaker technical trend signals (below key moving averages with negative MACD). Offsetting these are strong multi-year growth/profitability progress and constructive 2026 guidance, though a high P/E and margin/cash-conversion pressure limit upside in the near term.
Positive Factors
Scale & revenue growth
Sustained multi-year top-line expansion demonstrates durable market penetration and demand across core categories. High revenue growth provides bandwidth to invest in product development, marketing and international expansion, reducing per-unit fixed costs and supporting longer-term margin improvement.
Negative Factors
Marked increase in leverage
The abrupt shift to materially higher leverage reduces financial flexibility and raises refinancing and interest-rate risks. Elevated debt levels limit optionality for opportunistic investments and increase vulnerability to any slowdown in revenue or margin performance over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Scale & revenue growth
Sustained multi-year top-line expansion demonstrates durable market penetration and demand across core categories. High revenue growth provides bandwidth to invest in product development, marketing and international expansion, reducing per-unit fixed costs and supporting longer-term margin improvement.
Read all positive factors
Hims & Hers Health (HIMS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.43B
Dividend YieldN/A
Average Volume (3M)37.52M
Price to Earnings (P/E)56.9
Beta (1Y)2.35
Revenue Growth78.02%
EPS Growth28.15%
CountryUS
Employees1,637
SectorHealthcare
Sector Strength45
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)0.08
Shares Outstanding219,561,140
10 Day Avg. Volume20,191,059
30 Day Avg. Volume37,524,219
Financial Highlights & Ratios
PEG Ratio-33.00
Price to Book (P/B)13.50
Price to Sales (P/S)3.11
P/FCF Ratio98.76
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue2.26
Enterprise Value/Gross Profit3.06
Enterprise Value/Ebitda33.02
Forecast
1Y Price Target
$26.36Price Target Upside35.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)0.41
Revenue Forecast (FY)$2.76B
Hims & Hers Health Business Overview & Revenue Model
Company Description
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and...
How the Company Makes Money
Hims & Hers primarily makes money by selling healthcare products and services directly to consumers through its digital platform, with revenue largely driven by recurring subscriptions. Key revenue streams include: (1) Subscriptions and recurring ...
Hims & Hers Health Key Performance Indicators (KPIs)
Any
Subscriptions
Tracks the number of active subscriptions, highlighting recurring revenue streams and customer retention strength.
Tracks the number of active subscriptions, highlighting recurring revenue streams and customer retention strength.
Data provided by:
The Fly
The FlyHims & Hers Health Earnings Call Summary
Earnings Call Date:Feb 23, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Positive
The call conveyed strong commercial momentum and financial improvement: robust top-line growth (Q4 +28%, FY +59%), expanding profitability (adjusted EBITDA +~80%), growing subscriber base (>2.5M) and meaningful cash generation. Management emphasized rapid product launches, diagnostic and hormonal early successes, and aggressive international expansion via acquisitions. Offsetting these positives are near-term headwinds from fulfillment timing ($65M Q1 revenue timing impact), margin pressure from investments and international mix, regulatory uncertainty around compounded GLP-1s, and sizable acquisition-related commitments. Overall, fundamentals and strategic investments appear to outweigh the near-term risks, though execution and regulatory outcomes will be key to sustaining the trajectory.Positive Updates
Strong Revenue Growth
Revenue of $618M in Q4 2025, up 28% year-over-year; full-year 2025 revenue $2.35B, up 59% year-over-year.
Negative Updates
Regulatory and Legal Scrutiny on Compounded GLP-1s
Ongoing regulatory/legal scrutiny (FDA/DOJ conversations referenced) around compounding GLP-1s creates uncertainty; management highlighted the potential for restrictions and noted they pulled a pill product to prioritize stakeholder engagement.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Revenue Growth
Revenue of $618M in Q4 2025, up 28% year-over-year; full-year 2025 revenue $2.35B, up 59% year-over-year.
Read all positive updates
Company Guidance
Hims & Hers guided Q1 2026 revenue of $600–$625M (up ~2–7% y/y) and adjusted EBITDA of $35–$55M (≈7% margin at the midpoint), and full‑year 2026 revenue of $2.7–$2.9B (up ~15–24% y/y) with adjusted EBITDA of $300–$375M (implied ~12% margin at the midpoint); the outlook (which excludes the Eucalyptus deal) assumes an approximately $65M Q1 revenue timing headwind from the weight‑loss shift to 503(a) fulfillment (vs ~$40M in H2 2025) but not reduced demand (weight‑loss subscribers grew >70% y/y in Q4), includes expected first‑quarter EBITDA pressure from a 60‑second Super Bowl ad (marketing payback <1 year), anticipates at least $200M of international revenue in 2026 (with an additional ≥$200M in H2 if Eucalyptus closes), and reflects planned staged investments to scale Labs, low‑testosterone and menopause offerings, technology/AI, and international expansion (Eucalyptus consideration up to $1.15B with ~$240M upfront and combined international breakeven targeted in 12–18 months).Hims & Hers Health Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
48
Neutral
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.35B | 1.48B | 872.00M | 526.92M | 271.88M |
| Gross Profit | 1.73B | 1.17B | 714.95M | 408.72M | 204.49M |
| EBITDA | 160.12M | 78.99M | -19.94M | -61.22M | -110.97M |
| Net Income | 128.37M | 126.04M | -23.55M | -65.68M | -107.66M |
Balance Sheet | |||||
| Total Assets | 2.15B | 707.54M | 441.19M | 366.34M | 420.58M |
| Cash, Cash Equivalents and Short-Term Investments | 577.49M | 300.25M | 220.98M | 179.63M | 247.27M |
| Total Debt | 1.26B | 11.35M | 9.95M | 5.31M | 5.48M |
| Total Liabilities | 1.61B | 230.82M | 97.16M | 54.60M | 85.97M |
| Stockholders Equity | 540.93M | 476.72M | 344.03M | 311.74M | 334.62M |
Cash Flow | |||||
| Free Cash Flow | 73.96M | 198.33M | 46.99M | -33.78M | -39.42M |
| Operating Cash Flow | 300.01M | 251.08M | 73.48M | -26.53M | -34.41M |
| Investing Cash Flow | -1.02B | -19.05M | -12.11M | 34.70M | -156.27M |
| Financing Cash Flow | 729.62M | -107.84M | -11.47M | -33.13M | 235.04M |
Hims & Hers Health Technical Analysis
Negative
19.43
Price Trends
20.14
Negative
27.43
Negative
38.93
Negative
Market Momentum
-0.49
Positive
45.10
Neutral
30.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HIMS, the sentiment is Negative. The current price of 19.43 is below the 20-day moving average (MA) of 21.29, below the 50-day MA of 20.14, and below the 200-day MA of 38.93, indicating a bearish trend. The MACD of -0.49 indicates Positive momentum. The RSI at 45.10 is Neutral, neither overbought nor oversold. The STOCH value of 30.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HIMS.
Hims & Hers Health Risk Analysis
Hims & Hers Health disclosed 71 risk factors in its most recent earnings report. Hims & Hers Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Hims & Hers Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $3.89B | 33.71 | 22.89% | ― | 20.21% | 44.14% | |
62 Neutral | $750.24M | 31.72 | 4.84% | ― | 1.30% | ― | |
58 Neutral | $4.43B | 56.90 | 22.99% | ― | 78.02% | 28.15% | |
55 Neutral | $361.91M | 2.96 | 20.36% | 2.39% | -12.10% | ― | |
52 Neutral | $909.82M | -6.16 | -14.24% | ― | -2.37% | 77.85% | |
52 Neutral | $1.02B | -3.02 | -2.50% | 3.51% | -1.34% | -73.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HIMS
Hims & Hers Health
19.43
-8.88
-31.37%
NUS
Nu Skin
7.52
1.58
26.62%
TDOC
Teladoc
5.10
-2.14
-29.56%
EPC
Edgewell Personal Care
21.89
-7.34
-25.11%
GDRX
GoodRx Holdings
2.19
-2.30
-51.22%
DOCS
Doximity
21.05
-31.55
-59.98%
Hims & Hers Health Corporate Events
Business Operations and StrategyLegal Proceedings
Hims & Hers revamps GLP-1 strategy with Novo Nordisk
Positive
Mar 12, 2026
On March 9, 2026, Hims Hers announced a strategic overhaul of its U.S. weight-loss business, aligning it with its global model by prioritizing a wider range of FDA-approved GLP-1 medications and limiting the use of compounded semaglutide to selec...
Business Operations and StrategyM&A Transactions
Hims & Hers to Acquire Eucalyptus in Global Expansion
Positive
Feb 19, 2026
On February 19, 2026, Hims Hers Health agreed to acquire Australian digital health company Eucalyptus for up to $1.15 billion, in a deal structured with about $240 million payable in cash at closing, further deferred payments over 18 months, and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.